What Happened

Eledon Pharmaceuticals presented 18-month Phase 2 BESTOW trial data showing tegoprubart-treated kidney transplant patients maintained significantly higher eGFR (74 vs 61 mL/min/1.73 m²) with zero biopsy-proven acute rejection events after six months. The drug also showed superior patient-reported outcomes versus tacrolimus.

Who Is Affected

Transplant surgeons and nephrologists at academic medical centers running transplant programs. Pharmaceutical companies developing immunosuppressants will face new competition if tegoprubart succeeds in Phase 3.

Market Impact

• Challenges tacrolimus' $2B+ transplant immunosuppression market dominance
• Creates urgency for transplant centers to evaluate next-gen therapies
• Signals Eledon's readiness for Phase 3 investment in late 2026

What to Watch

Phase 3 trial initiation in late 2026 with primary endpoint comparing BPAR/graft loss/death versus tacrolimus at 52 weeks. Monitor adoption at key transplant centers participating in the extension study.